The Role of General Anesthetic Drug Selection in Cancer Outcome

Table 1

Outcome of cancer surgery and anesthesia.

Type of study	Cancer type	Outcome	Power	Reference
Retrospective	Various cancers	5-year mortality VA 22.8% vs. TIVA 15.6%		Wigmore et al. [5]
Retrospective	Breast cancer	5-year mortality no difference between sevoflurane and propofol arms	n.s.	Enlund et al. [7]
Retrospective	Breast cancer	No difference in recurrence-free survival between VA and TIVA		Kim et al. [8]
Retrospective	Breast cancer	Propofol arm had longer recurrence-free survival than sevoflurane arm; no difference in overall survival	(recurrence free); (survival)	Lee et al. [9]
Retrospective	Breast cancer	Propofol arm had longer recurrence-free survival than sevoflurane arm; no difference in overall survival		Huang et al. [10]
Retrospective	Breast cancer	No difference in recurrence-free survival between VA and TIVA		Yoo et al. [12]
Retrospective	Esophageal cancer	VA was associated with worse overall survival and recurrence-free survival	(overall survival, recurrence-free survival)	Jun et al. [15]
Retrospective	Gastric cancer	TIVA was associated with better overall survival than sevoflurane		Zheng et al. [16]
Retrospective	Gastric cancer	VA had higher 1-year mortality than TIVA		Oh et al. [17]
Retrospective	Colon cancer	Propofol had better 1-year and 5-year survival than sevoflurane	(1-year survival); (5-year survival)	Enlund et al. [7]
Retrospective	Colon cancer	Propofol had better survival than desflurane	-	Wu et al. [18]
Retrospective	Rectal cancer	No difference in 1-year and 5-year survival between propofol and sevoflurane	n.s.	Enlund et al. [7]
Retrospective	Hepatocellular cancer	Propofol had better survival than desflurane		Lai et al. [19]
Retrospective	Hepatocellular cancer	Propofol was associated with less 2-year recurrence survival than VA		Koo et al. [20]
Retrospective	Cholangiocarcinoma	Propofol was associated with better survival than desflurane		Lai et al. [21]
Retrospective	Non-small-lung cancer	No difference in overall survival and recurrence-free survival between TIVA and sevoflurane	(overall survival); (recurrence-free survival)	Oh et al. [22]